 Home > Medical News > Latest Medical News > AstraZeneca over US$3.5 billion and Ionis to develop a new antisense oligonucleotide drug under development

AstraZeneca over US$3.5 billion and Ionis to develop a new antisense oligonucleotide drug under development

 Last Update: 2021-12-31
 Source: Internet
 Author: User

Tags

fda drug regulations

atherosclerotic cardiovascular disease

leading type

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On December 7, AstraZeneca and Ionis Pharmaceuticals (hereinafter referred to as "Ionis") announced that an antisense oligonucleotide (ASO) eplontersen (IONIS-TTR-LRX) of the latter under development has reached over 35.

According to the terms of the agreement, the two parties will jointly develop and commercialize eplontersen in the United States, and AstraZeneca will obtain the right to develop and commercialize eplontersen in regions other than Latin America

Amyloid transthyretin cardiomyopathy (ATTR-CM) is a systemic, progressive, and fatal disease that can lead to progressive heart failure and death within 4 years of diagnosis

Eplontersen is a ligand-coupled antisense oligonucleotide therapy under development, which aims to reduce the production of transthyretin (TTR) protein to treat all types of transthyretin-mediated amyloidosis (ATTR)

Reference materials:

[1] AstraZeneca and Ionis sign deal to develop and commercialise eplontersen.

(The original text has been deleted)

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.